Latest Property Portfolio News

Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.

Tryptamine Therapeutics reported a $5.33 million loss for FY25 while progressing key clinical trials of its psychedelic therapies and strengthening its leadership team. The company secured $6 million in funding and launched a world-first trial targeting Binge Eating Disorder.

Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.

CTI Logistics reported modest revenue growth and a strong EBITDA increase in FY25, underpinned by a significant property valuation uplift and strategic capital investments. The company is poised for sustainable growth amid a consolidating freight market.

Centuria Industrial REIT has expanded its exchangeable notes offering to $325 million, reflecting robust investor appetite, while simultaneously repurchasing nearly all its existing notes due 2028.

Australian Unity Office Fund reports a $35.6 million loss for FY25 as it advances asset disposals ahead of planned delisting, with the final property sale facing settlement uncertainty.

Tetratherix Limited advances its Tetramatrix biomaterial platform with a robust IP portfolio, scalable manufacturing, and strategic partnerships aimed at commercialising across multiple clinical franchises.

Cromwell Property Group reported a 15% drop in revenue and a 21% fall in operating profit for FY2025, yet significantly reduced its losses and net debt, signaling cautious progress amid challenging market conditions.

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

BluGlass Limited reported a 16% rise in revenue to $11.7 million for FY25, driven by key US Department of Defense contracts and new partnerships. However, the company’s net loss increased 8% to nearly $11 million amid ongoing R&D investment and operational scaling.

Race Oncology Limited reported a significantly reduced loss for FY2025, driven by key clinical trial progress and strategic leadership changes. The company advances its RC220 program with promising Phase 1 dosing milestones and strengthens its governance to support future growth.

CVC Limited has reversed its fortunes with a $0.5 million net profit after tax for FY25, driven by strong property investment income and strategic land developments, while maintaining a cautious capital management approach and withholding dividends.